Semaglutide Clinic Darwin: Weight Loss Prescribers and Eligibility

Eligibility in Australia: Wegovy vs Ozempic

Semaglutide is supplied in Australia as Wegovy (for chronic weight management) and Ozempic (for type 2 diabetes). Eligibility is assessed by a doctor based on Australian guidance and the approved Product Information (PI).

Wegovy (semaglutide) for weight management

• Adults with BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one weight‑related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, pre‑diabetes)

Prescribers generally follow RACGP and ANZ obesity guidance alongside the TGA-approved PI/CMI.

References: TGA Wegovy CMI • TGA • RACGP – Obesity management overview • ANZOS pharmacotherapy position statements

Ozempic (semaglutide) for type 2 diabetes

• Indicated to improve glycaemic control in adults with type 2 diabetes, usually when metformin and/or other agents are insufficient
• PBS subsidy criteria apply for eligible patients; weight loss alone is not a PBS indication

References: TGA Ozempic CMI • PBS – Ozempic listing

Off‑label boundaries and TGA guidance

During shortages and as a general prescribing principle, Ozempic should not be prescribed for weight loss when not clinically indicated and when weight‑management brands are available. See TGA shortage and safety communications.

References: TGA Medicine Shortages database • TGA – Ozempic shortage updates

Ask a doctor about eligibility

Typical dosing and titration (evidence-based outline)

Your prescriber will individualise dosing. A commonly used, label‑aligned titration for Wegovy is:

• 0.25 mg once weekly for 4 weeks
• 0.5 mg once weekly for 4 weeks
• 1.0 mg once weekly for 4 weeks
• 1.7 mg once weekly for 4 weeks
• 2.4 mg once weekly as maintenance (if tolerated)

If side effects occur, your doctor may extend a step or temporarily reduce to the prior tolerated dose. For Ozempic in type 2 diabetes, standard schedules differ; follow the PI/CMI and clinician advice.

References: TGA Wegovy CMI/PI • TGA Ozempic CMI/PI

Get a personalised plan

Safety, interactions and key warnings

• Gastrointestinal effects are common at initiation and dose increases (nausea, vomiting, diarrhoea, constipation). Escalate slowly and maintain hydration.
• Hypoglycaemia risk increases when combined with insulin or sulfonylureas. Your doctor may adjust other diabetes medicines.
• Renal considerations: severe vomiting/diarrhoea can lead to dehydration and acute kidney injury, particularly in those with pre‑existing renal impairment.
• Gallbladder and pancreatitis: report persistent severe abdominal pain promptly. History of pancreatitis requires careful evaluation.
• Thyroid C‑cell tumours: contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.
• Gastric emptying: semaglutide can delay gastric emptying, which may affect absorption of critical oral medicines (e.g., contraceptives, narrow‑therapeutic‑index drugs). Discuss timing/backup contraception and monitoring with your prescriber.
• Pregnancy and breastfeeding: not recommended. Use effective contraception and stop if planning pregnancy.
• Compounded products: the TGA has issued warnings and restrictions regarding compounded semaglutide; use approved, quality‑assured medicines only.

References: TGA Wegovy CMI • TGA Ozempic CMI • TGA – warnings re: compounded/illegally supplied weight loss products

Speak with a clinician

Semaglutide pricing in Darwin (private and PBS)

Prices vary by pharmacy and stock. The ranges below are typical private cash prices observed nationally and in NT. Always confirm with your chosen Darwin pharmacy before prescribing. All prices are indicative only.

Wegovy private prices (weight management)

• Starter doses (0.25 mg / 0.5 mg): typically $199–$299 per pen
• 1.0 mg: typically $249–$329 per pen
• 1.7 mg: typically $289–$349 per pen
• 2.4 mg maintenance: typically $329–$449 per pen

Ozempic private prices (when not PBS-eligible)

• 1 mg pen: typically $129–$169
• 2 mg pen: typically $169–$229

PBS co‑payment (Ozempic for eligible type 2 diabetes)

• As at April 2026: up to $31.60 (general) and up to $7.70 (concession), subject to annual indexation. Check current amounts with Services Australia or your pharmacist.

References: PBS – Ozempic listing and criteria • PBS – Wegovy search (not PBS for obesity at time of writing)

Price check date: 18 April 2026.

Get a cost estimate

Darwin availability and how to check stock

Supply can fluctuate. Before or after your consult, you can:

• Check national updates: TGA Medicine Shortages database and Novo Nordisk Australia announcements.
• Phone major Darwin pharmacies (CBD, Casuarina, Palmerston, Nightcliff) and ask about current stock or ordering timelines; request to join a waitlist.
• Ask your prescriber to note acceptable strength alternatives on the script if clinically appropriate.
• If out of stock, discuss bridging options and follow‑up timing with your doctor.

References: TGA Medicine Shortages database • Novo Nordisk Australia – supply updates • Pharmacy Guild – Find a Pharmacy

Ask us to check your local stock

How to find a local prescriber or pharmacy in Darwin

• Search AHPRA for a GP or endocrinologist and confirm current registration.
• Use NT Health to locate nearby clinics and chronic disease services.
• Use Find a Pharmacy to identify pharmacies that can order Wegovy or dispense Ozempic.

Helpful links: AHPRA register • NT Health service finder • Find a Pharmacy

Request a local referral

What your appointment looks like

1. Pre-screening: BMI, medical history, medicines, pregnancy intentions, lifestyle factors.
2. Consult (telehealth or in-person): eligibility, risks, benefits, shared decision-making, and baseline measurements.
3. Script and pharmacy plan: identify a Darwin pharmacy, confirm stock/ordering, and set follow‑up.
4. Titration and follow‑up: dose increases every ~4 weeks if tolerated, side‑effect management, and behavioural support.

Start pre-screening

Frequently asked questions (Darwin)

Key Australian references

• TGA – Wegovy CMI/PI
• TGA – Ozempic CMI/PI
• TGA – Medicine Shortages database
• TGA – Ozempic shortage guidance
• TGA – Compounded/illegal weight-loss products warning
• PBS – Ozempic listing and criteria
• RACGP – Obesity management overview
• ANZOS – Obesity pharmacotherapy position statements

Get help applying this locally

Summary

For Darwin residents, Wegovy may be appropriate for eligible weight management, while Ozempic remains for type 2 diabetes under PBS criteria. Start with a qualified prescriber, use approved products, follow a slow titration, and check stock proactively with local pharmacies and TGA updates.

Start your semaglutide pathway